Stabilized coronavirus spike (s) protein immunogens and related vaccines

Patent metadata

Field	Value
Publication number	US-12448416-B2
Application number	US-202318503260-A
Country	US
Kind code	B2
Filing date	Nov 7, 2023
Priority date	Jun 29, 2020
Publication date	Oct 21, 2025
Grant date	Oct 21, 2025

Abstract

The present invention provides redesigned soluble coronavirus S protein derived immunogens that are stabilized via specific modifications in the wildtype soluble S sequences. Also provided in the invention are nanoparticle vaccines that contain the redesigned soluble S immunogens displayed on self-assembling nanoparticles. Polynucleotide sequences encoding the redesigned immunogens and the nanoparticle vaccines are also provided in the invention. The invention further provides methods of using the vaccine compositions in various therapeutic applications, e.g., for preventing or treating coronaviral infections.

First claim

What is claimed is:

1. An engineered immunogen polypeptide derived from the spike(S) protein of a coronavirus, comprising an altered soluble S sequence that has modifications relative to wildtype soluble S sequence of the coronavirus that stabilize the prefusion S structure, wherein the modifications comprise (a) a mutation that inactivates the S1/S2 cleavage site, and (b) a truncation of the heptad repeat 2 region (HR2).

2. The immunogen polypeptide of claim 1 , further comprising (1) a mutation in the turn region between the heptad repeat 1 (HR1) region and the central helix (CH) region that prevents HR1 and CH to form a straight helix during fusion, and (2) a truncation of one or more residues beyond the HR2 region and/or a mutation in HR1 region that disrupts formation of a helical fusion core.

3. The immunogen polypeptide of claim 2 , wherein the coronavirus is SARS-CoV-2, wherein the mutation inactivating S1/S2 cleavage site comprises substitution of 682 RRAR 685 (SEQ ID NO:19) with GSAG (SEQ ID NO:20), and the mutation in the turn region comprises double mutation K986G/V987G, K986P/V987P, K986G/V987P or K986P/V987G, wherein the amino acid numbering is based on SARS-COV-2 Wuhan-Hu-1 isolate.

4. The immunogen polypeptide of claim 3 , wherein the wildtype soluble S sequence comprises SEQ ID NO:14, or a variant with at least 99% sequence identity.

5. The immunogen polypeptide of claim 4 , wherein the truncated HR2 comprises SEQ ID NO:9.

6. The immunogen polypeptide of claim 5 , further comprising a trimerization motif at the C-terminus.

7. The immunogen polypeptide of claim 6 , wherein the trimerization motif comprises foldon set forth in SEQ ID NO:26 or viral capsid protein SHP set forth in SEQ ID NO:27.

8. The immunogen polypeptide of claim 5 , comprising the sequence shown in any one of SEQ ID NOs:32-37, or a variant thereof with at least 99% sequence identity.

9. A polynucleotide sequence that encodes the immunogen polypeptide of claim 1 .

10. The polynucleotide sequence of claim 9 , encoding a fusion polypeptide comprising the immunogen polypeptide that is fused at its C-terminus to the N-terminus of the subunit sequence of a self-assembling nanoparticle.

11. A coronavirus immunogenic composition, comprising the immunogen polypeptide of claim 2 that is displayed on the surface of a self-assembling nanoparticle.

12. The immunogenic composition of claim 11 , wherein the self-assembling nanoparticle comprises a trimeric sequence, and wherein C-terminus of the immunogen polypeptide is fused to N-terminus of the subunit sequence of the nanoparticle.

13. The immunogenic composition of claim 11 , wherein the self-assembling nanoparticle comprises I3-01, E2p or ferritin.

14. The immunogenic composition of claim 11 , further comprising a locking domain and/or a T-cell epitope that is fused to the C-terminus of the nanoparticle subunit sequence.

15. The immunogenic composition of claim 11 , comprising: (1) a polypeptide sequence containing from N terminus to C terminus (a) an engineered SARS-COV-2 spike polypeptide, a GS linker sequence, and nanoparticle sequence I3-01v9, (b) an engineered SARS-CoV-2 spike polypeptide, a GS linker sequence, and nanoparticle sequence E2p, or (c) an engineered SARS-COV-2 spike polypeptide, a GS linker sequence, and nanoparticle sequence ferritin; or (2) a variant of the polypeptide sequence with at least 99% sequence identity.

16. The immunogenic composition of claim 15 , wherein the engineered SARS-CoV-2 spike immunogen polypeptide comprises (a) substitution of the S1/S2 cleavage site 682RRAR685 with GSAG, (b) double mutations K986G/V987G in the turn region, and (c) truncation of HR2 set forth in SEQ ID NO:9 at the C-terminus of the wildtype soluble S sequence; wherein the amino acid numbering is based on SARS-COV-2 Wuhan-Hu-1 isolate.

17. The immunogenic composition of claim 15 , wherein the engineered SARS-CoV-2 spike immunogen polypeptide comprises SEQ ID NO:33 or 34, or a variant thereof with at least 99% sequence identity.

18. The immunogenic composition of claim 17 , comprising (1) a polypeptide sequence containing from N terminus to C terminus (a) the engineered SARS-COV-2 spike polypeptide shown in SEQ ID NO:33, linker sequence shown in SEQ ID NO:22, nanoparticle sequence shown in SEQ ID NO:23, locking domain shown in SEQ ID NO:29, and T cell epitope shown in SEQ ID NO:30, (b) the engineered SARS-COV-2 spike polypeptide shown in SEQ ID NO:33, linker sequence shown in SEQ ID NO:21, nanoparticle subunit sequence shown in SEQ ID NO:24, locking domain shown in SEQ ID NO:28, and T cell epitope shown in SEQ ID NO:30, or (c) the engineered SARS-COV-2 spike polypeptide shown in SEQ ID NO:33, linker sequence shown in SEQ ID NO:21, nanoparticle sequence shown in SEQ ID NO:25; or (2) a variant of the polypeptide sequence with at least 99% sequence identity.

19. The immunogenic composition of claim 17 , comprising the sequence shown in any one of SEQ ID NOs:38-40, or a variant thereof with at least 99% sequence identity.

20. A method for inhibiting a SARS-COV-2 infection in a subject, comprising administering to the subject a pharmaceutically effective amount of the immunogenic composition of claim 11 .

Assignees

• Scripps Research Inst

Inventors

• He Linling
• Zhu Jiang
• Wilson Ian A

Classifications

• A61P31/14 Primary

  for RNA viruses · CPC title

• A61K2039/57

  characterised by the type of response, e.g. Th1, Th2 · CPC title

• C12N2770/20034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2770/20022

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• A61K2039/575

  humoral response · CPC title